

## UBS (Lux) Equity SICAV – USA Growth (USD) I-A1-acc

## Data as of the end of February 2022

## **Portrait**

- The fund invests mainly in US growth stocks
- The portfolio is constructed on the basis of a quantitative model and forward-looking fundamental analysis
- Risk management is a core element of our disciplined asset management process
- The investment goal is to outperform the benchmark over a full Value/Growth cycle
- The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
- UBS Growth Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS funds pursue an active management style, each fund's performance can deviate substantially from that of its reference index. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Securities no.	4,732,789
ISIN	LU0399032613
Reuters symbol	=
Bloomberg Ticker	UUGI70A LX
Currency of account	USD
Issue/redemption	daily
Management fee p.a.	0.560%
Flat fee	0.700%
Swing pricing	yes
TER (as of 31.05.2021	0.72%
Benchmark	Russell 1000 Growth (net div. reinv.) in USD


Current data		
Net asset value 28.2.2022	USD	587.88
– high last 12 months	USD	682.65
– low last 12 months	USD	510.38
Assets of the unit class in m	USD	419.76
Fund assets in m	USD	1,623.28
Last distribution		reinvested

Key risk figures (annualised)		
	2 years	3 years
Tracking error	3.18%	3.01%
Beta	0.99	1.01
Correlation	0.99	0.99
Total risk	21.47%	19.57%
Sharpe ratio	1.18	1.07
Risk-free rate (5 years) = 1.22%		

The statistical ratios were calculated on the basis of logarithmic returns.

Sectors (in %)		
	Portfolio	Benchmark
IT	42.93	46.36
Consumer discretionary	19.65	18.10
Telecommunication services	13.45	10.71
Health care	12.09	8.78
Industrials	7.22	6.08
Financial system	1.41	2.54
Consumer staples	1.33	4.31
Energy	0.97	0.45
Real estate	0.00	1.67
Materials and supplies	0.00	0.97
Utilities	0.00	0.03
Others	0.95	0.00
Total	100.00	100.00

Performance (in %)		
	Portfolio	Benchmark
03.2021	-0.15	1.70
04.2021	7.55	6.79
05.2021	-1.97	-1.41
06.2021	5.73	6.25
07.2021	2.74	3.28
08.2021	2.92	3.72
09.2021	-4.68	-5.62
10.2021	9.16	8.65
11.2021	-0.55	0.59
12.2021	1.71	2.10
01.2022	-8.88	-8.59
02.2022	-3.08	-4.27
2022 YTD	-11.69	-12.50
2021	25.83	27.32
2020	36.17	38.08
2019	37.37	35.88
2018	0.14	-1.89
2017	32.20	29.67
Ø p.a. 2 years	25.53	27.10
Ø p.a. 3 years since end of fund launch month	21.90	22.82
12.2009	489.53	506.45



Past performance is no guarantee of future trends. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

10 largest positions (in %)		
	Portfolio	Benchmark
Alphabet Inc	8.84	6.51
Apple	8.73	12.28
Amazon Com Inc	8.10	6.42
Microsoft	7.66	10.85
Visa Inc	4.20	1.76
Top 5	37.53	37.82
Nvidia Corporation	3.59	2.81
Abbvie Inc	3.38	1.26
Union Pac Corp	3.01	0.48
Applied Matls Inc	2.77	0.58
Transdigm Group Inc	2.44	0.05
Top 10	52.72	43.00



## UBS (Lux) Equity SICAV – USA Growth (USD) I-A1-acc

Data as of the end of February 2022

For marketing and information purposes by UBS. For professional clients / qualified investors only, UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information adoptions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Dutins of UBS funds mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the person